Table 2 Characteristics of breakthrough IFD episodes (n=20)
Epidemiological characteristics | |
|---|---|
Male sex | 10 (50%) |
Age (years) | 9.5 (6.5-15) |
Underlying conditions | |
ALL | 6 (30%) |
AML | 6 (30%) |
SOT | 1 (5%) |
Non-malignant blood disorders | 7 (35%) |
HSCT | 11 (55%) |
Allogeneic | 10/11 |
Autologous | 1/11 |
Risk stratification | |
High-risk | 19 (95%) |
Low-risk | 1 (5%) |
Sporadic | 0 |
Type of AFP | |
Micafungin (intravenous formulation) | 13 (65%) |
Fluconazole (oral formulation) | 4 (20%) |
Posaconazole (oral formulation) | 2 (10%) |
Itraconazole (oral formulation) | 1 (5%) |
IFD diagnosis | |
Proven IFD | 0 |
Probable IFD | 8 (40%) |
Possible IFD | 12 (60%) |
Type of infection | |
Mold infection | 20 (100%) |
Yeast infection | 0 |
Site of disease | |
Bronchopulmonary | 20 (100%) |
Rhino-sinusitis | 2 (10%) |
Outcome | |
PICU admission | 6 (30%) |
Mechanical ventilation | 3 (15%) |
Inotropic support | 2 (10%) |
Exitus | 5 (25%) |